Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.5247
- Book/Share 8.0497
- PB 5.6139
- Debt/Equity 0.0817
- CurrentRatio 3.7516
- ROIC 0.2536
- MktCap 12116055211.0
- FreeCF/Share 2.8948
- PFCF 15.5926
- PE 17.8933
- Debt/Assets 0.0625
- DivYield 0
- ROE 0.3164
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | Morgan Stanley | Overweight | Equal Weight | -- | $48 | Jan. 8, 2026 |
| Downgrade | EXEL | BofA Securities | Neutral | Underperform | -- | $41 | Jan. 5, 2026 |
| Initiation | EXEL | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
| Downgrade | EXEL | Guggenheim | Buy | Neutral | -- | -- | Nov. 3, 2025 |
| Upgrade | EXEL | Leerink Partners | Market Perform | Outperform | -- | $48 | Oct. 21, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 19, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 17, 2025 |
| Initiation | EXEL | Goldman | -- | Buy | -- | $47 | Sept. 17, 2025 |
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
News
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
EXEL or TECH: Which Is the Better Value Stock Right Now?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Published: February 21, 2025 by: Benzinga
Sentiment: Positive
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Read More
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Read More
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Citi Gregory Renza - RBC Capital Markets Eva Fortea-Verdejo - Wells Fargo Jason Gerberry - Bank of America Securities Andy Hsieh - William Blair …
Read More
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Exelixis Posts 63.7% Profit Surge
Published: February 11, 2025 by: The Motley Fool
Sentiment: Neutral
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year-over-year figures by 18.2%.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael Morrissey
- Employees 1147